Cryo-Cell International, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)

9 Months Ended

Aug. 31, 2022

Variables used to determine the fair value of the options granted for the three and nine months ended August 31, 2022 and 2021, respectively, are as follows:


	Three months ended		Nine months ended
	August 31, 2022	August 31, 2021	August 31, 2022	August 31, 2021
Weighted average values:
Expected dividends	—	—	0%	0%
Expected volatility	—	—	53.23%	49.85%
Risk free interest rate	—	—	2.74%	1.35%
Expected life	—	—	3 years	6 years

Stock Option Activity

Stock option activity for options with only service-based vesting conditions for the nine months ended August 31, 2022, was as follows:


				Weighted		Weighted Average Remaining
				Average		Contractual		Aggregate
	Options			Exercise Price		Term (Years)		Intrinsic Value
Outstanding at November 30, 2021		537,443		$	5.76	5.22		$	3,564,067
Granted		52,500			13.20				—
Exercised		(182,229	)		3.03				645,304
Expired/forfeited		(87,250	)		6.15				150,075
Outstanding at August 31, 2022		320,464		$	8.42		4.73	$	136,007
Exercisable at August 31, 2022		231,230		$	7.27		5.04	$	136,007

Significant Option Groups Exercisable Option and its Price and Contractual Life

Significant option groups outstanding and exercisable at August 31, 2022 and related price and contractual life information are as follows:


	Outstanding						Exercisable
			Weighted Average
			Remaining		Weighted				Weighted
Range of Exercise Prices	Outstanding		Contractual Life (Years)		Average Exercise Price		Outstanding		Average Exercise Price
$3.01 to $4.00		30,000		2.99	$	3.13		30,000	$	3.13
$6.01 to $7.00		3,833		3.84	$	6.52		3,833	$	6.52
$7.01 to $8.00		196,531		5.16	$	7.63		179,879	$	7.60
$9.01 to $10.00		29,000		5.51	$	9.37		7,800	$	9.36
$12.01 to $13.00		16,653		7.98	$	12.54		9,718	$	12.63
$13.01 to $14.00		44,447		2.31	$	13.50		0	$	0.00
		320,464		4.73	$	8.42		231,230	$	7.27

Summary of Non-Vested Options

A summary of the status of the Company’s non-vested options as of August 31, 2022, and changes during the nine months ended August 31, 2022, is presented below:


				Weighted Average
				Grant-Date
	Options			Fair Value
Non-vested at November 30, 2021		63,034		$	4.99
Granted		52,500			4.56
Vested		(18,634	)		5.83
Forfeited		(7,666	)		6.23
Non-vested at August 31, 2022		89,234		$	4.45